TWT-101 (Treadwell Therapeutics, Inc.)
Description: A First In-Human, Phase I/II Study of CFI-402411, Hematopoietic Progenitor Inase-1 (HPK1) Inhibitor, As A Single Agent and In Combination With Pembrolizumab In Subjects With Advanced Solid Malignancies
Mechanism of Action: HPK1 inhibitor (blocks a novel critical negative regulator in the activation of T lymphocytes and dendritic cells)
Target Patient Population: Non small cell lung cancer, Small cell lung cancer, Squamous cancers of Head and Neck, Anal or Skin, Urothelial, Renal Cell, Triple Negative Breast , Endometrial, Cervical, Gastroesophageal, Hepatocellular or any MSI-H cancer.
Study Design: Drug is given orally daily.